Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 222

1.

Imaging modalities in synchronous oligometastatic prostate cancer.

Futterer JJ, Surcel C, van den Bergh R, Borgmann H, Briganti A, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere PJL, Tsaur I; EAU-YAU Prostate Cancer Working Party.

World J Urol. 2018 Aug 1. doi: 10.1007/s00345-018-2416-2. [Epub ahead of print]

PMID:
30069582
2.

Accuracy of 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography for the Detection of Lymph Node Metastases Before Salvage Lymphadenectomy.

Mandel P, Tilki D, Chun FK, Pristupa E, Graefen M, Klutmann S, Budäus L, Steuber T.

Eur Urol Focus. 2018 Jul 23. pii: S2405-4569(18)30191-3. doi: 10.1016/j.euf.2018.07.025. [Epub ahead of print]

PMID:
30049657
3.

Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.

Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol. 2018 Jul 20. pii: S0302-2838(18)30484-6. doi: 10.1016/j.eururo.2018.07.006. [Epub ahead of print]

PMID:
30037529
4.

Getting the Balance Right-The Benefits and Uncertainties of Focal Therapy for Significant Prostate Cancer.

Murphy DG, Tilki D.

Eur Urol. 2018 Jul 11. pii: S0302-2838(18)30463-9. doi: 10.1016/j.eururo.2018.06.035. [Epub ahead of print] No abstract available.

PMID:
30007818
5.

Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies?

Ploussard G, Borgmann H, Briganti A, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R; EAU-YAU Prostate Cancer Working Group.

World J Urol. 2018 Jul 2. doi: 10.1007/s00345-018-2399-z. [Epub ahead of print]

PMID:
29967944
6.

Antimicrobial Lubricant Did Not Reduce Infection Rate in Transrectal Biopsy Patients in a Large Randomized Trial Due to Low Complication Rates.

Salomon G, Prues S, Saul J, Budäus L, Tilki D, Schneider M, Haferkamp A, Graefen M, Boehm K.

Eur Urol Focus. 2018 Jun 22. pii: S2405-4569(18)30153-6. doi: 10.1016/j.euf.2018.06.005. [Epub ahead of print]

PMID:
29941389
7.

Anterior Localization of Prostate Cancer Suspicious Magnetic Resonance Imaging Lesions in Patients Undergoing Initial and Repeat Biopsy: Results from 1,161 Patients Undergoing Magnetic Resonance Imaging/Ultrasound Fusion Guided Targeted Biopsies.

Leyh-Bannurah SR, Kachanov M, Beyersdorff D, Preisser F, Tilki D, Fisch M, Graefen M, Budäus L.

J Urol. 2018 Jun 20. pii: S0022-5347(18)43405-2. doi: 10.1016/j.juro.2018.06.026. [Epub ahead of print]

PMID:
29935274
8.

Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer.

Wilczak W, Wittmer C, Clauditz T, Minner S, Steurer S, Büscheck F, Krech T, Lennartz M, Harms L, Leleu D, Ahrens M, Ingwerth S, Günther CT, Koop C, Simon R, Jacobsen F, Tsourlakis MC, Chirico V, Höflmayer D, Vettorazzi E, Haese A, Steuber T, Salomon G, Michl U, Budäus L, Tilki D, Thederan I, Fraune C, Göbel C, Henrich MC, Juhnke M, Möller K, Bawahab AA, Uhlig R, Adam M, Weidemann S, Beyer B, Huland H, Graefen M, Sauter G, Schlomm T.

Eur Urol. 2018 Sep;74(3):376-386. doi: 10.1016/j.eururo.2018.05.034. Epub 2018 Jun 13.

PMID:
29908878
9.

Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection.

Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Urol Oncol. 2018 Aug;36(8):365.e1-365.e7. doi: 10.1016/j.urolonc.2018.05.019. Epub 2018 Jun 7.

PMID:
29887241
10.

Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database.

Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30123-8. doi: 10.1016/j.euf.2018.05.006. [Epub ahead of print]

PMID:
29802052
11.

In-hospital length of stay after major surgical oncological procedures.

Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI.

Eur J Surg Oncol. 2018 Jul;44(7):969-974. doi: 10.1016/j.ejso.2018.05.001. Epub 2018 May 9.

PMID:
29784507
12.

How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.

Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaur I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP).

BJU Int. 2018 May 17. doi: 10.1111/bju.14391. [Epub ahead of print]

PMID:
29772103
13.

Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems.

Pompe RS, Beyer B, Haese A, Preisser F, Michl U, Steuber T, Graefen M, Huland H, Karakiewicz PI, Tilki D.

BJU Int. 2018 May 4. doi: 10.1111/bju.14369. [Epub ahead of print]

PMID:
29727912
14.

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.

Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI.

World J Urol. 2018 Sep;36(9):1399-1407. doi: 10.1007/s00345-018-2310-y. Epub 2018 May 2.

PMID:
29717358
15.

Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.

Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat SF, Huland H, Graefen M, Briganti A, Karakiewicz PI.

Prostate. 2018 Jul;78(10):753-757. doi: 10.1002/pros.23519. Epub 2018 Apr 16.

PMID:
29663462
16.

Robotic-assisted vs. open radical prostatectomy: an update to the never-ending debate.

Chandrasekar T, Tilki D.

Transl Androl Urol. 2018 Mar;7(Suppl 1):S120-S123. doi: 10.21037/tau.2017.12.20. No abstract available.

17.

Are clinical guidelines designed according to guidelines? Cross-sectional assessment of quality and transparency of clinical guidelines in urology.

van den Bergh RCN, Ost P, Surcel C, Valerio M, Fütterer JJ, Gandaglia G, Sooriakumaran P, Tilki D, Tsaur I, Ploussard G; European Association of Urology Working Party on Prostate Cancer (EAU-YAUWP).

World J Urol. 2018 Sep;36(9):1489-1494. doi: 10.1007/s00345-018-2278-7. Epub 2018 Apr 2.

PMID:
29610962
18.

Reply to the letter to the editor: RE: Preisser F, et al. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. 2018;1-7.

Preisser F, Bandini M, Graefen M, Tilki D, Karakiewicz PI.

Prostate. 2018 Jun;78(9):692. doi: 10.1002/pros.23521. Epub 2018 Apr 2. No abstract available.

PMID:
29607522
19.

The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy.

Tilki D, Preisser F, Karakiewicz P, Shariat SF, Graefen M, Huland H, Chun FK, Pompe RS.

World J Urol. 2018 Aug;36(8):1247-1253. doi: 10.1007/s00345-018-2274-y. Epub 2018 Mar 26.

PMID:
29582100
20.

Local treatment for metastatic prostate cancer: A systematic review.

Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP.

Int J Urol. 2018 May;25(5):390-403. doi: 10.1111/iju.13535. Epub 2018 Mar 23. Review.

PMID:
29572963

Supplemental Content

Loading ...
Support Center